tbuckley/cabot-search huggingface dataset:
FDG PET/CT Evaluation of Treatment Response in Patients With Recurrent Colorectal Cancer
Authors: Shamim Ahmed Shamim, Rakesh Kumar, Varun Shandal, Dhanapathi Halanaik, Guresh Kumar, Chandra Shekhar Bal, Arun Malhotra
Journal: Clinical Nuclear Medicine (2010)

to evaluate the treatment response in patients with recurrent colorectal cancer (CRC) using FDG PET/CT.a total of 32 recurrent CRC patients (21 males, 11 females; mean age, 52.8 years) were included in this retrospective study. All patients underwent a baseline and follow-up FDG PET/CT scans after chemotherapy. Of 32 patients, 23 patients had follow-up carcinoembryonic antigen (CEA) levels.on qualitative analysis of baseline and follow-up FDG PET/CT studies, there were 20 nonresponders and 12 were responders. On quantitative analysis, there were 19 nonresponders and 13 were responders. In responders, baseline and follow-up mean SUV(max) were 11.8 ± 10.1 and 3.7 ± 4.1, respectively (significant decrease, P = 0.001). Among nonresponders, baseline and follow-up mean SUV(max) were 8.1 ± 5.2 and 14.1 ± 9.0, respectively (significant increase, P = 0.003). There was no association between response and different factors like age, sex, diagnosis, extent of the lesions, and number of lesions.FDG PET/CT appears to be useful modality in evaluating chemotherapy response and can differentiate responders from nonresponders in recurrent CRC patients.
Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors
Authors: Charles D. Blanke, Ronald P. DeMatteo
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 3736: Correlates of vitamin D: A measurement pilot study
Authors: Alana D. Steffen, Peter Gies, Robert Cooney
Journal: Cancer Research (2011)

Abstract Vitamin D has protective effects for colorectal cancer and possible benefits for breast and ovarian cancers yet the determinants of vitamin D status are not fully understood. This study measured sun exposure, sun protection, diet, body mass index, and skin color and correlated them with serum 25(OH)D to understand better the impact of these factors on vitamin D status. Women (n=28) ages 18-30 residing in Hawaii attended small group sessions where they completed questionnaires about diet, supplement use, and skin type and had skin color measured by reflectance spectrophotometry. Participants wore polysulphone dosimeters mounted on wristbands, photographed clothing outfits and kept daily diaries for the 7 days before their blood draw. Results: Participants were, on average, 24.6 (3.3) years old, had BMI of 23.6 (range 17.7 – 34.7), consumed 308 IU vitamin D daily (range 10 – 1202), used sunscreen on 12% of their body (range 0 to 44%), were 44% covered by clothing (range 22 – 79%), received 2.3 standard erythemal doses (range .1 to 5.9) of UVB and had 34.7 ng/mL of 25(OH)D3 (range 17.7 – 90.5). Personal UVB dose accounted for 22% of the variance in 25(OH)D, and the addition of clothing and sunscreen coverage increased the R2 value to 0.33. Skin color and diet were not associated with 25(OH)D. While BMI was showed an association 25(OH)D, it did not improve the model and was inversely related to UVB exposure. While the measured sun-related variables were useful for predicting 25(OH)D, the majority of variance in vitamin D status is unexplained. More research is needed to understand how this hormone is regulated in the body. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3736. doi:10.1158/1538-7445.AM2011-3736
Identification of the Skin Basement-Membrane Autoantigen in Epidermolysis Bullosa Acquisita
Authors: David T. Woodley, Robert A. Briggaman, Edward J. O'Keefe, Alfred O. Inman, Laurinda L. Queen, W. Ray Gammon
Journal: New England Journal of Medicine (1984)

Epidermolysis bullosa acquisita is an acquired chronic blistering disease of the skin, in which separation of the skin occurs in the basement-membrane zone between the epidermis and the dermis. There is evidence that blistering is initiated by an immune process. Using serum samples from nine patients as a source of antibodies, we have identified a major protein of the basement membrane of human skin that serves as the antigen (or target) for autoantibodies in this disorder. This previously unrecognized protein, which consists of two components of 290,000 and 145,000 daltons, is distinct from other known components of the basement membrane. These studies provide evidence that epidermolysis bullosa acquisita is a specific disease that is different from other primary bullous diseases, such as bullous pemphigoid and pemphigus vulgaris, and suggest that the basement-membrane component that has been identified may have a role in normal epidermal–dermal adherence. (N Engl J Med 1984; 310:1007–13.)
SERUM URIC ACID IS ASSOCIATED WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL
Authors: Axel Åkerblom, Stefan James, Maria Bertilsson, Anders Himmelmann, Monika Huhn, Karen Pieper, Steen Husted, Robert Storey, Richard Becker, Lars Wallentin
Journal: Journal of the American College of Cardiology (2016)
Further Observations Concerning the Salivary Transport of Iodide
Authors: Norbert Freinkel, Sidney H. Ingbar
Journal: New England Journal of Medicine (1955)

RECENTLY Thode, Jaimet and Kirkwood,1 of Hamilton, Ontario, reported excellent correlation between thyroidal status and the ratios obtained when the concentration of I131 in mixed saliva (that is, serous and mucous) was related to either total or protein-bound radioactivity in the plasma twenty-four hours after administration of the tracer. Ratios in hyperthyroid patients were markedly lower and in myxedematous patients markedly higher than those found in normal subjects.§ It was suggested that the saliva test might "provide additional information concerning thyroid-salivary function as well as an excellent diagnostic test."In a previous publication2 we reported that ratios of salivary I . . .
Risk of Stroke in Male Cigarette Smokers
Authors: Robert D. Abbott, Yin Yin, Dwayne M. Reed, Katsuhiko Yano
Journal: New England Journal of Medicine (1986)

From 1965 to 1968, the Honolulu Heart Program began following 8006 men of Japanese ancestry in a prospective study of cardiovascular disease. Of the subjects who had not had a stroke by the time of study entry, 3435 were cigarette smokers and 4437 were nonsmokers. In 12 years of follow-up, 171 smokers and 117 nonsmokers had a stroke. As compared with nonsmokers, cigarette smokers had two to three times the risk of thromboembolic or hemorrhagic stroke, after control for age, diastolic blood pressure, coronary heart disease, and other risk factors (P less than 0.001). Subjects who continued to smoke in the course of follow-up had the highest risk of stroke. When these subjects were compared with those who never smoked, their risk of hemorrhagic events was increased four- to six-fold (P less than 0.001). Subjects who were smokers at study entry but stopped smoking in the course of follow-up had a slight excess risk of stroke. When these subjects were compared with those who continued to smoke, however, their risk was reduced by more than half after adjustment for risk factors (P less than 0.05), indicating that stopping smoking had significant benefits.
ARTHROPLASTY OF THE TEMPOROMAXILLARY JOINT
Authors: FULTON RISDON
Journal: JAMA (1925)

To state briefly the anatomy of the temporomaxillary joint and its associated parts, first, from the osseous standpoint, there is the condyle and its neck, the sigmoid notch and the coronoid process. Overlying these structures, we have the zygomatic process and its anterior root, which is broad and strong, to terminate in a rounded eminence, the eminentia articularis. This eminence forms the anterior boundary of the glenoid fossa, and in the recent state is covered with cartilage. The middle root forms the posterior boundary of the mandibular portion of the glenoid fossa. The glenoid fossa is bounded posteriorly by the vaginal and auditory processes. The junction of the anterior root with the zygoma is a projection called the tubercle, for attachment of the external lateral ligament of the lower jaw. Between the anterior and middle roots is an oval depression forming part of the glenoid fossa for the reception of
LONG-TERM PROGNOSTIC VALUE OF CARDIAC HYBRID IMAGING INTEGRATING SINGLE-PHOTON-EMISSION COMPUTED TOMOGRAPHY WITH CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY
Authors: Aju Pazhenkottil, Dominik Benz, Christoph Gräni, Fran Mikulicic, Beatrice Hirt Moch, Michael Madsen, Jan Vontobel, Oliver Gaemperli, Ronny Buechel, Thomas F. Lüscher, Philipp A. Kaufmann, Cardiac Imaging
Journal: Journal of the American College of Cardiology (2016)
Incidental Detection of Colorectal Cancer Via 18F-Choline PET/CT in a Patient With Recurrent Prostate Cancer
Authors: Oreste Bagni, Luca Filippi, Orazio Schillaci
Journal: Clinical Nuclear Medicine (2015)

A 74-year-old man with history of prostate cancer underwent 18F-choline PET/CT for restaging. Early acquisition of the pelvic region revealed intense uptake in prostate, with infiltration of the posterior wall of the bladder. Furthermore, focal uptake in the thickened anterior wall of the rectum was detected. Whole-body scan at 60 minutes confirmed early findings in pelvis, although the infiltration of the bladder was no more evident due to interference of radioactive urine. Biopsy demonstrated the presence of colorectal carcinoma. The dual-phase protocol resulted in significant clinical impact to clearly characterize focuses of abnormal 18F-choline uptake in the pelvic region.
Sources of Concern about the Patient Self-Determination Act
Authors: Susan M. Wolf, Philip Boyle, Daniel Callahan, Joseph J. Fins, Bruce Jennings, James Lindemann Nelson, Jeremiah A. Barondess, Dan W. Brock, Rebecca Dresser, Linda Emanuel, Sandra Johnson, John Lantos, DaCosta R. Mason, Mathy Mezey, David Orentlicher, Fenella Rouse
Journal: New England Journal of Medicine (1991)

ON December 1, 1991, the Patient Self-Determination Act of 1990 (PSDA)1 went into effect. This is the first federal statute to focus on advance directives and the right of adults to refuse life-sustaining treatment. The law applies to all health care institutions receiving Medicare or Medicaid funds, including hospitals, skilled-nursing facilities, hospices, home health and personal care agencies, and health maintenance organizations (HMOs). The statute requires that the institution provide written information to each adult patient on admission (in the case of hospitals or skilled-nursing facilities), enrollment (HMOs), first receipt of care (hospices), or before the patient comes under an . . .
P717HuR mediate the sinergistic effects of Angiotensin II and interleukin 1beta on vascular COX-2 expression and cell migration
Authors: A Aguado Martinez, O Zhenyukh, C Rodriguez, J Martinez, M S Avendanno, L Garcia Redondo, M J Alonso, A M Briones, D Dixon, M Salaices
Journal: Cardiovascular Research (2014)

Purpose. Angiotensin II (Ang II) and interleukin 1b (IL-1β) are involved in cardiovascular diseases inducing pro-inflammatory enzymes such as cyclooxygenase 2 (COX-2). COX-2 is an early response gene regulated by its transcription and by mRNA stability. Our purpose was to evaluate whether Ang II potentiates the effect of IL-1β on COX-2 expression and activity, the mechanisms involved in this effect and the functional consequence of this interaction. Methods. Rat aortic smooth muscle cells were stimulated with IL-1b or Ang II+IL-1b (4 or 24 h). mRNA and protein levels were measured by qPCR and western blot, respectively. The COX-2 promoter and 3'UTR activity were measured by luciferase assay. Immunofluorescence and cellular fractionation were used to analyze HuR cytoplasmic translocation. The binding of HuR to COX-2 mRNA was assessed by immunoprecipitation. Cell proliferation was analyzed by a commercial kit and cell migration by wound healing and transwell. In a mouse carotid ligation model, COX-2, mPGES-1 and TXAS were measured by immunohistochemistry. Results. 1) IL-1b (10 ng/ml) increased COX-2, mPGES-1 and TXAS expression. 2) Ang II (0.1 mM) increased PGIS and TXAS expression and potentiated and decreased, respectively, COX-2 and mPGES-1 expression induced by IL-1b. 3) The potentiation of COX-2 expression was accompanied by increased mRNA stability and 3'UTR luciferase activity. These effects were blocked by ERK1/2 and HuR inhibitors. 4) Ang II+IL-1b promoted HuR translocation to the cytoplasm and its binding to COX-2 mRNA. 5) Ang II did not affect cell proliferation but potentiated cellular migration induced by IL-1b; this effect was abolished by inhibitors of COX-2, TXAS, ERK1/2 and HuR and by antagonists of TP, EP-1 and EP-3 receptor. 6) PGE2 and a TXA2 analogue increased the cellular migration. 7) After the carotid ligation, COX-2, mPGES-1 and TXAS expression were increased. Conclusions. 1) Ang II differentially modulates COX-2, mPGES-1, PGIS and TXAS vascular expression induced by IL-1b. 2) The potentiation of IL-1β-induced COX-2 expression evoked by Ang II is mediated by ERK1/2 and it is due to an increase in the COX-2 mRNA stability mediated by HuR. 3) TXA2 and PGE2 derived from COX-2 participate in the effects of Ang II plus IL-1β on cell proliferation. 4) These effects could contribute to the vascular pro-inflammatory actions of Ang II and IL-1b.
PTU-100 Decompensated Alcoholic Liver Disease (ALD) is Associated with Starting Heavy Drinking at an Older Age: a Case-Control Study: Abstract PTU-100 Table
Authors: D Gleeson, A K Ali, J S Jones, M Bradley, R J Peck, K M McCormack
Journal: Gut (2013)

<h3>Introduction</h3> The relationship between development of ALD (which affects only 10–15% of heavy drinkers) and rate, duration and age of onset of alcohol consumption is incompletely understood. We have previously reported on total lifetime alcohol consumption in two cohorts of heavy drinkers ( &gt; 60 Units/wk(M) or &gt; 40 Units/wk(F) for ≥ 5 years): one (patients) with decompensated ALD (Child Grade B or C, negative tests for other liver diseases) and one (controls) without serious liver disease on clinical, laboratory and ultrasound examination. Here, we aimed to compare alcohol consumption patterns in these cohorts in more detail. <h3>Methods</h3> Subjects (330 patients, 234 male, mean age 48 yr and 238 heavy-drinking controls, 187 male, mean age 48 yr) completed a lifetime alcohol questionnaire. Alcohol consumption was calculated at home and outside home, and during Monday-Thursday and Friday-Sunday. Data were summed over each stable drinking period during the subject’s lifetime. We calculated (a) total duration, and age at start and at cessation of all periods during which the subject drank &gt; 0, &gt; 40, &gt; 80, &gt; 120 and &gt; 160 units(U)/wk and (b) percent of drinking career engaged in: regular drinking, drinking &lt; 5 days per week, weekend drinking and not drinking. <h3>Results</h3> Neither total duration of periods consuming &gt; 0, &gt; 40, &gt; 80, &gt; 120, and &gt; 160 U alcohol/wk (table) mean weekly consumption during those periods (not shown) differed significantly between patients and controls. However, patients first started drinking over each level at an older age than did controls (table). The relationships between ALD and age of starting drinking &gt; 0, &gt; 40, &gt; 80, &gt; 120 and &gt; 160 U/week persisted in multivariate analysis (p = 0.00–0.013). Subjects spent 83(63–97)% of their careers in regular drinking, with no case-control differences. <h3>Conclusion</h3> Development of decompensated ALD in heavy drinkers is associated with starting heavy drinking at an older age. <h3>Disclosure of Interest</h3> None Declared <h3>Reference</h3> J Hepatol 2012; 56:S53
Abstract 878: <i>In vitro</i> selection of metastatic breast cancer cells based on their adaptability
Authors: Balraj Singh, Milan R. Raythatha, Amanda M. Cady, Simran Madan, Karen Tai, LaTashia R. Irving, Anthony Lucci
Journal: Cancer Research (2012)

Abstract The success of cancer depends on ongoing generation of genetic and epigenetic heterogeneity in cancer cells, and the selection of cells that are most adaptable at surviving numerous obstacles in the body. Current approaches of personalized therapy, mostly designed to inhibit cell proliferative function of a single protein, may not succeed unless we target adaptability of cancer cells as well. We reported recently that it is possible to isolate highly metastatic rare cancer cells (&amp;lt; 0.01% in SUM149 inflammatory breast cancer cell line) based on their adaptability to survive without glutamine in culture medium. These studies also provided evidence of a high COX-2 expression in such Gln-independent cells and in subpopulations that survived lack of serum and attachment. To determine the usefulness of our new function-based selections, we compared different COX-2 overexpressing subpopulations with the parental SUM149 cell line for their adaptability to survive lack of Gln- 1) COX-2 overexpressing cells that survive lack of serum and attachment (designated SWS), and 2) a pre-existing COX-2 overexpressing clone (clone 5) isolated by picking individual colonies. We found that the SWS variants yielded significantly more colonies (2-3 fold) than the parental cell line upon Gln withdrawal. In contrast, clone 5 failed to yield any Gln-ind colony. Further investigation into the adaptability of Gln-ind cells revealed that they are better able to survive exposure to hypoxia than the parental cell line. We obtained similar results with hypoxia caused by cell culture in 0.5% oxygen or with hypoxia caused by exposure to cobalt chloride. These results support a model in which rare cells that drive metastasis are proposed to be adaptable in multiple ways. Our studies suggest that the function-based selection of adaptable cancer cells is able to select unique cancer cells from a heterogeneous population that may not be selectable on the basis of specific biomarkers. We conclude that it is feasible to isolate rare metastatic breast cancer cells with a function-based robust selection of adaptable metabolic state. In vitro assays utilizing such adaptable and metastatic cancer cells will likely aid anti-cancer drug discovery efforts. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 878. doi:1538-7445.AM2012-878
NCI Appropriations Law Not Expected Until Fall
Authors: B. Duane
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article NCI Appropriations Law Not Expected Until Fall Get access Betsy Duane Betsy Duane Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 14, 15 July 1992, Pages 1073–1074, https://doi.org/10.1093/jnci/84.14.1073 Published: 15 July 1992
Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes Mellitus
Authors: A Garg, S M Grundy
Journal: New England Journal of Medicine (1988)

Coronary heart disease is an important cause of death in patients with non-insulin-dependent diabetes mellitus (NIDDM) and is particularly common in diabetic populations that have relatively high levels of plasma cholesterol. To determine whether plasma cholesterol levels in patients with NIDDM could be reduced by drug therapy, we assessed the effect of lovastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in a randomized double-blind placebo-controlled manner in 16 white patients with NIDDM and mild to moderate elevations of plasma cholesterol. Lovastatin (20 mg twice daily) or a placebo was given for four weeks, during which blood glucose concentrations remained controlled. As compared with the placebo, lovastatin reduced total cholesterol by 26 percent, low-density lipoprotein (LDL) cholesterol by 28 percent, and LDL apolipoprotein B by 26 percent. Lovastatin therapy also reduced plasma triglycerides and very-low-density lipoprotein cholesterol by 31 percent and 42 percent, respectively. Although there was no change in the plasma level of high-density lipoprotein (HDL) cholesterol, the ratio of total cholesterol to HDL cholesterol fell by 29 percent. No side effects or abnormalities in serum values were noted during short-term lovastatin therapy. The beneficial effects of lovastatin on plasma lipid levels in patients with NIDDM could decrease the risk of the development of coronary heart disease.
Abstract 603: Adenoviral mediated expression of Omomyc induced growth inhibition and apoptosis in lung cancer expressing Myc
Authors: Takuya Fukazawa, Junji Matsuoka, Tomoki Yamatsuji, Yutaka Maeda, Mary Durbin, Yoshio Naomoto
Journal: Cancer Research (2010)

Abstract The Myc basic helix-loop-helix zipper domain determines dimerization with the constitutively expressed bHLH-Zip protein, Max, and also binding to the DNA E-box. Both of these functions play a critical role in the Myc regulation of growth, proliferation, tumorigenesis, and apoptosis. It has been reported that Myc recognition specificity is encoded in a short region within the leucine zipper. Mutation of four amino acids (E57T, E64I, R70Q, and R71N) generates a protein, Omomyc, that homodimerizes efficiently and can still heterodimerize with wild type Myc and Max. As a consequence, Omomyc suppresses activation of artificial E-box promoter elements by Myc/Max and strongly potentiates Myc-induced apoptosis in a manner dependent on Myc expression levels. Furthermore, Omomyc prevents initiation of K-RasG12D-induced lung tumors (Soucek L et al. Oncogene. 17: 2463-72. 1998, Nature. 455:679-83. 2008). In this study we have constructed an adenoviral vector (Ad-Omomyc) for use as a novel therapy for Myc or K-Ras mutated cancer. Ad-Omomyc expresses Omomyc and is driven by the CMV promoter. MTS assay and flowcytometric analysis demonstrated that Ad-Omomyc significantly suppressed cell viability and induced apoptosis in A549 pulmonary adenocarcinoma cells, which express Myc and harbor K-Ras mutations. Moreover, the combination treatment of Ad-Myc and Ad-Omomyc increased apoptosis in H441 pulmonary adenocarcinoma cells harboring a K-Ras mutation as compared to administering Ad-Omomyc alone. Ad-Omomyc induced little apoptosis in normal human lung fibroblasts (NHLF). Here, we describe a novel strategy to target Myc or K-Ras for the treatment of lung cancer using a Myc derivative: Omomyc. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 603.